Boston Scientific (BSX) Q3 2026 (USD): adj. EPS 0.73 (exp. 0.72), Revenue 5.14bln (exp. 5.06bln). Current FY adj. EPS 3.16-3.18 (exp. 3.22)

Boston Scientific (BSX) Q3 2026 (USD): adj. EPS 0.73 (exp. 0.72), Revenue 5.14bln (exp. 5.06bln). Current FY adj. EPS 3.16-3.18 (exp. 3.22)

The print follows a familiar pattern for large-cap medtech: a modest beat on the quarter paired with full-year guidance that brackets or falls short of the street, and in episodes of this kind the guidance line has tended to dominate the tape reaction over the quarterly beat. The distinction worth drawing is whether the softer full-year range reflects demand and procedural volumes, which would be read across the peer set, or margin and mix items such as integration costs from recent acquisitions, foreign exchange, or tariff and supply chain drag, which are more idiosyncratic. Boston Scientific has historically been one of the steadier growers in the group, so a guide-down of this size is against its usual form and will put weight on the call for explanation. The transmission channel into peers runs through procedure volumes and hospital capital spending commentary rather than through the EPS line itself. Worth watching is management's framing on the call: organic growth versus reported, commentary on electrophysiology and WATCHMAN-type franchises, and any split between temporary and structural drivers of the guidance cut.